Discover
llllllllll brazikumab (AMG 139) / AstraZenecaBrazikumab: Data from P2b/3 INTREPID trial (NCT03759288) for Crohn’s disease in 2021 or later (AstraZeneca) - Jul 30, 2020 - H1 2020 Results: Data from P3 trial (NCT03961815) for Crohn’s disease in 2021 or later [Screenshot]llllllllll Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi: Data from P3 KEEPsAKE 1 trial (NCT03675308) for psoriatic arthritis in 2020 (AbbVie) - Aug 1, 2020 - Q2 2020 Results: Data from P3 trial (NCT03105102) for Crohn's disease in Q4 2020/Q1 2021llllllllll brazikumab (AMG 139) / AstraZenecaBrazikumab: Data from P2 EXPEDITION trial (NCT03616821) for ulcerative colitis in 2021 or later (AstraZeneca) - Jul 30, 2020 - H1 2020 Results: Data from P2 trial (NCT04277546) for ulcerative colitis in 2021 or later [Screenshot]llllllllll Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi: Regulatory submissions for Crohn’s disease and psoriatic arthritis in 2021 (AbbVie) - Aug 1, 2020 - Q2 2020 Resultsllllllllll Rinvoq (upadacitinib) / AbbVieRinvoq: Top-line data from P3 trial (NCT03006068) for ulcerative colitis in 2020 (AbbVie) - Aug 1, 2020 - Q2 2020 Resultsllllllllll Humira (adalimumab) / Eisai, AbbVie; Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimAbbVie Reports Second-Quarter 2020 Financial Results (AbbVie Press Release) - Jul 31, 2020 - "AbbVie...announced financial results for the second quarter ended June 30, 2020....Global Humira net revenues of $4.837 billion decreased 0.7 percent on a reported basis, or 0.2 percent on an operational basis. U.S. Humira net revenues were $3.974 billion, an increase of 4.8 percent. Internationally, Humira net revenues were $863 million, a decrease of 19.9 percent on a reported basis...due to biosimilar competition. Global Skyrizi net revenues were $330 million. Global Rinvoq net revenues were $149 million....Global Botox Therapeutic net revenues were $297 million, a decrease of 22.3 percent on a comparable operational basis, due to the COVID-19 pandemic....Global Ubrelvy net revenues were $22 million."llllllllll Remsima SC (infliximab biosimilar SC) / CelltrionEuropean Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima SC, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis (Businesswire) - Jul 27, 2020 - "Celltrion Healthcare today announced that the European Commission (EC) has granted marketing authorisation for Remsima® (infliximab, CT-P13) subcutaneous (SC) formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis....We will accelerate the launch process on a country-by-country basis...Celltrion anticipates receiving approval of Remsima® SC in 97 countries, including 31 countries in Europe."llllllllll mirikizumab (LY3074828) / Eli LillyMirikizumab: Primary completion of P3 LUCENT 2 trial (NCT03524092) in moderate-to-severe ulcerative colitis in Mar 2021 (Eli Lilly) - Jul 31, 2020 - Q2 2020 Results: Primary completion of P3 LUCENT-ACT trial (NCT04469062) for ulcerative colitis in Mar 2024; Completion of P3 LUCENT-ACT trial for ulcerative colitis in Jun 2024 [Screenshot]
